The following post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a financial partner of Benzinga.
Making a difference is what Medexus Pharmaceuticals Inc. MDPMEDXF says it is all about. In an ocean of big pharma drug makers like Pfizer Inc. PFE, Johnson & Johnson JNJ or Amgen Inc. AMGN, Medexus — with 2021 U.S. revenue of $79.7 million, 15 products on the market and a 117% 3-year compound average growth rate — positions its focus on helping patients who might be left out.
As a leading innovative and rare disease pharmaceutical company, Medexus’ differentiated portfolio of high-value orphan and rare disease products underpins decades of growth in a sector that matters.
Improving the Quality and Length of Life
Medexus believes that the research and development that it drives forward have yielded innovative treatments, with more in the pipeline:
- Rasuvo and Metoject treat rheumatoid arthritis, a market projected to reach $63 billion in the U.S. by 2027.
- IXINITY® controls bleeding in older patients with Hemophilia B, a $1 billion global market, and is currently in trials for pediatric use.
- Rupall relieves severe allergies in a market valued at $131.4 million and growing at an annual rate of 17%.
- Treosulfan, a conditioning agent used prior to stem cell transplantation, improves outcomes in treating cancers like leukemia, which is expected to be a $17 billion global market by 2024.
- Gleolan, a powder-based imaging agent, makes deadly glioma brain tumors fluoresce under blue light, with the brain tumor treatment market estimated to grow into a $5.64 billion market in the U.S. by 2028.
Managing Is Good; Curing Is Better
One of Medexus’ most beneficial medicines, treosulfan, is an orphan-designated agent developed to improve outcomes for patients undergoing allogeneic stem cell transplantation when faced with cancer like leukemia.
As explained by the Canadian Cancer Society, if an allogeneic stem cell transplant is done during 1st remission, the 5-year, disease-free survival rate is 30% to 50%. If no recurrence appears 2 years after transplant, the person has about an 80% chance of staying in complete remission for a long period of time.
Because it fills an unmet need that current treatments are not meeting, physicians use treosulfan for its efficacy, tolerability, and increased survival rates.
Healing Patients Profitably?
Medexus says it melds investor value with social good. One of its signature drugs, IXINITY®, treats hemophiliacs. With its strong safety profile, it currently taps less than 4% of the U.S. market share with 17% patients switching per year and studies to expand into pediatric care that could increase market size by 30%.
Medexus CEO Ken d’Entremont, noted, “The Hemophilia B market in the U.S. alone is estimated to be in excess of $1 billion. A label expansion inclusive of the pediatric market represents a significant market opportunity for IXINITY. If approved, we expect to be well-positioned to commercialize quickly with the infrastructure we already have in place for the adult market.”
Treosulfan, a warrior in the assault against leukemia, is also set to grow.
“We completed a transformative licensing deal for treosulfan in the United States and materially enhanced our ability to fund our growth initiatives, with the completion of an oversubscribed financing of $32.5 million,” d’Entremont said. “This investment will be the key to supporting and enabling the significant revenue growth that we expect from treosulfan.”
For people with rare diseases, opportunities can be limited. Medexus says it is a strong bet in a growing market, offers solutions for people with little hope, and throws a valuable lifeline in a sea of doubt.
Learn more about Medexus here.
The preceding post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a financial partner of Benzinga. Although the piece is not and should not be construed as editorial content, the sponsored content team works to ensure that any and all information contained within is true and accurate to the best of their knowledge and research. This content is for informational purposes only and not intended to be investing advice.
© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.